According to the information received by gore: on june 08 2015 this patient underwent an endovascular treatment of a peripheral arterial disease with a gore® propaten® vascular graft.Reportedly on (b)(6) 2015, an adverse event termed "thrombosis of gore bypass" was identified, an intervention was performed on the same date and the patency of the was restored.However according to reports, on (b)(6) 2015, a graft rethrombosis was discovered.It was recorded that an intervention was performed immediately on the same date.The patency of the graft was restored by the end of the procedure.The primary relationship was indicated to be disease related and the physician confirmed that the stent graft didn't cause or contribute to the adverse event.
|
A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.H10 b14: a review of the manufacturing records indicated the lot met pre-release manufacturing specifications.H3 other h10 code b20: evaluation of the device could not be conducted because it remains implanted.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|